The research advances of a new theory: right-and left-sided colon cancer may be two different kinds of clinical disease

doi:10.3877/cma.j.issn.2095-3224.2016.05.003

Abstract

Abstract:

Recently, researchers gradually discovered that the right and left colon cancer has significant difference in molecular mechanism of carcinogenesis, it was possibly due to intestinal epithelium derives from different embryologic origin. Patients with right-sided colon cancer were more likely to be elder, women and poorly differentiated. Frequencies of CIMP+ , MSI+ , BRAF+ were higher in right-sided colon cancer. The prognostic differences between right-and left-colon cancer were associated with tumor stage. For stageⅠthe survival was similar. Right-sided cancer had better survival for stage Ⅱ, but worse survival for stage Ⅲ/Ⅳ. Colorectal cancer origined from different location had different biological behavior, and it should not be regarded as a single entity. In the current era of personalized and precision medicine, tumor locations was quite important in the evaluation of prognosis and drug efficacy.

Key words: Colorectal neoplasms, Pathology, Prognosis, Genetic variation

Junjie Hu, Zhiguo Xiong. The research advances of a new theory: right-and left-sided colon cancer may be two different kinds of clinical disease[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(05): 380-385.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.05.003

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I05/380

References 37

[1]	Siegel R,Desantis C,Jemal A. Colorectal cancer statistics, 2014[J]. CA: Cancer J Clin, 2014, 64(2): 104-117.
[2]	Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location[J]. Ann Intern Med, 1990, 113(10): 779-788.
[3]	Boise MK,Johansen JS,Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer[J]. Annals of Oncology, 2013, 24(10): 2554-2559.
[4]	Ramesh O,Rana D,Habibollah M, et al. Anatomical Distribution of Colorectal Carcinoma in Iran: A Retrospective 15-yr Study to Evaluate Rightward Shift[J].Asian Pacific J Cancer Prev,2012,13(1),279-282.
[5]	Cheng L,Eng C,Nieman LZ, et al. Trends in colo-rectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005[J]. Am J Clin Oncol, 2011, 34(6): 573-580.
[6]	Weiss JM,Pfau PR,O'Connor ES, et al. Mortality by stage for right-versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results-Medicare data[J]. J Clin Oncol: official journal of the American Society of Clinical Oncology, 2011, 29(33): 4401-4409.
[7]	Wu, X,Chen, VW,Martin J, et al. Sub-site-specific colorectal cancer incidence rates and stage distributions among Asians an d Pacific Islanders in the United States, 1995 to 1999[J]. Cancer Epidemiol. Biomarkers Prev, 2004, 13(7): 1215-1222.
[8]	Araki K,Furuya Y,Kobayashi M, et al. Comparison of mucosal microvasculature between the proximal and distal human colon[J]. J Electron Microsc (Tokyo), 1996, 45(3): 202-206.
[9]	Skinner SA,O'Brien PE. The microvascular structure of the normal colon in rats and humans[J]. J Surg Res, 1996, 61(2): 482-490.
[10]	Roncucci L,Modica S,Pedroni M,et al. Aberrant crypt foci in patients with colorectal cancer[J]. Br J cancer, 1998, 77(12): 2343-2348.
[11]	Roncucci L,Medline A,Bruce WR. Classification of aberrant crypt foci and microadenomas in human colon[J]. Cancer Epidemiol Biomarkers Prev, 1991, 1(1): 57-60.
[12]	Bara J,Nardelli J,Gadenne C, et al. Differences in the expression of mucus-associated antigens between proximal and distal human colon adenocarcinomas[J]. Br J cancer, 1984, 49(4): 495-501
[13]	Sun Y,O'Riordan MX. Regulation of bacterial pathogenesis by intestinal short-chain Fatty acids[J]. Adv Appl Microbiol, 2013, 85: 93-118.
[14]	Macfarlane GT,Gibson GR,Cummings JH. Comparison of fermentation reactions in different regions of the human colon[J]. J Appl Bacteriol, 1992, 72(1): 57-64.
[15]	Povey AC,Hall CN,Badawi AF, et al. Elevated levels of the pro-carcinogenic adduct, O(6)-methylguanine, in normal DNA from the cancer prone regions of the large bowel[J]. Gut, 2000, 47(3): 362-365.
[16]	Payne CM,Bernstein C,Dvorak K,et al. Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis[J]. Clin Exp Gastroenterol, 2008, 1: 19-47.
[17]	Lax S,Schauer G,Prein K, et al. Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis[J]. Int J Cancer Journal international du cancer, 2012, 130(10): 2232-2239.
[18]	Worthley DL,Leggett BA. Colorectal cancer: molecular features and clinical opportunities[J]. Clin Biochem Rev, 2010, 31(2): 31-38.
[19]	Reichmann A,Levin B,Martin P. Human large-bowel cancer: correlation of clinical and histopathological features with banded chromosomes[J]. Int J Cancer, 1982, 29(6): 625-629.
[20]	Delattre O,Olschwang S,Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer[J]. Lancet, 1989, 2(8659): 353-356.
[21]	Rothberg PG,Spandorfer JM,Erisman MD, et al. Evidence that c-myc expression defines two genetically distinct forms of colorectal adenocarcinoma[J]. Br J Cancer, 1985, 52(4): 629-632.
[22]	Russo A,Bazan V,Iacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53mutation: influence of tumor site, type of mutation, and adjuvant treatment[J]. J Clin Oncol, 2005, 20, 23(30): 7518-7528.
[23]	Weisenberger DJ,Siegmund KD,Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer[J]. Nat Genet, 2006, 38(7): 787-793.
[24]	Nosho K,Irahara N,Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample[J]. PloS One, 2008, 3(11): e3698.
[25]	Roth AD,Delorenzi M,Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage Ⅱ/Ⅲ colon cancer[J]. J Natl Cancer Inst. 2012, 104(21): 1635-1646.
[26]	Barault L,Charon-Barra C,Jooste V, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases[J]. Cancer Res, 2008, 68(20): 8541-8546.
[27]	Bae JM,Kim JH,Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location[J]. Br J Cancer, 2013, 109(4): 1004-1012.
[28]	Yokota T,Ura T,Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer[J]. Br J Cancer, 2011, 104(5): 856-862.
[29]	Hampel H,Frankel WL,Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer[J]. J Clin Oncol, 2008, 26(35): 5783-5788.
[30]	Hinojosa MW,Konyalian VR,Murrell ZA, et al. Outcomes of right and left colectomy at academic centers[J]. Am Surg, 2007, 73(10): 945-948.
[31]	Kwaan MR,Al-Refaie WB,Parsons HM, et al. Are right-sided colectomy out-comes different from left-sided colectomy outcomes?: study of pa-tients with colon cancer in the ACS NSQIP database[J]. JAMA Surg, 2013, 148(6): 504-510.
[32]	Meguid RA,Slidell MB,Wolfgang CL, et al. Is there a difference in survival between right-versus left-sided colon cancers[J]? Ann Surg Oncol, 2008, 15(9): 2388-2394.
[33]	Price TJ,Beeke C,Ullah S, et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease[J]? Cancer, 2015, 121(6): 830-835.
[34]	Ishihara S,Nishikawa T,Tanaka T, et al. Prognostic impact of tumor location in stage IV colon cancer: a propensity score analysis in a multicenter study[J]. Int J Surg, 2014, 12(9): 925-930.
[35]	Modest DP,Jung A,Moosmann N, et al.The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial[J]. Int J Cancer, 2012, 131(4): 980-986.
[36]	Brule SY,Jonker DJ,Karapetis CS, et al. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): nCIC CTG CO.17. J Clin Oncol, 2013, 31, (suppl, abstr 3528). Epub 2013 ASCO annual Meeting.
[37]	von Einem JC,Heinemann V,von Weikersthal LF, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial[J]. J Cancer Res Clin Oncol, 2014, 140(9): 1607-1614.

Please choose a citation manager

Content to export